Drug intelligence / Profile preview

CD229 CAR T cells

Development stage
Preclinical
Lead developer
University of Utah
Modality
CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration
Intravenous
01

Overview

CD229 CAR T cells are genetically engineered T-cell therapies designed to target CD229 (also known as Ly9 or SLAMF3), a cell-surface receptor belonging to the signaling lymphocytic activation molecule (SLAM) family. CD229 is highly and uniformly expressed on malignant plasma cells in multiple myeloma, including myeloma stem cells, as well as on various B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma, chronic lymphocytic leukemia (CLL), and follicular lymphoma. Developed by researchers at the University of Utah and the University of Maryland, CD229 CAR T cells utilize an anti-CD229 single-chain variable fragment (scFv) coupled with intracellular signaling domains (such as CD3ζ and 4-1BB) to selectively bind and eliminate CD229-expressing tumor cells. Preclinical studies have demonstrated potent cytotoxicity against multiple myeloma and B-cell malignancies, including activity against CD19-deficient tumor cells, suggesting potential utility in patients who relapse after CD19-targeted CAR T-cell therapies.

Other names
anti-CD229 CAR T cellsanti-CD-229 CAR T cellsanti-CD 229 CAR T cellsCD229 CAR-TCD-229 CAR-TCD 229 CAR-TCD229 CAR-T cellsCD-229 CAR-T cellsCD 229 CAR-T cellsCD229-directed CAR T cellsCD-229-directed CAR T cellsCD 229-directed CAR T cellsCD229-targeted CAR T cellsCD-229-targeted CAR T cellsCD 229-targeted CAR T cells
02

Targets

Beyond the preview

Go deeper on CD229 CAR T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD229 CAR T cells.

Work on CD229 CAR T cells? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call